Glenmark Pharmaceuticals Ltd. announced on Thursday, April 9, that it has received final approval from the US Food and Drug Administration (USFDA) for its Progesterone Vaginal Inserts, 100 mg. According to the company's exchange filing, the approved product is bioequivalent and therapeutically equivalent to Endometrin Vaginal Inserts, a reference drug of Ferring Pharmaceuticals. The product will be marketed in the United States through its subsidiary, Glenmark Pharmaceuticals Inc., USA. As reported by The Hindu BusinessLine, the approval covers progesterone vaginal inserts of strength 100 mg specifically designed for fertility treatments.
According to IQVIA data, the Endometrin market recorded annual sales of about $59.2 million for the 12 months ending February 2026. As reported by The Hindu BusinessLine, this moderate commercial opportunity indicates a significant market presence for Glenmark's new generic product. The product is typically used in women's healthcare, particularly in fertility-related treatments and represents a specialized therapeutic segment within the pharmaceutical market.
Marc Kikuchi, President and Business Head, North America, commented on the development, stating that "This approval for Progesterone Vaginal Inserts, 100 mg marks an important addition to our business and reinforces our focus on addressing patient needs in women's healthcare." According to the company, this approval marks another addition to Glenmark's growing portfolio of US generics as it continues to expand its presence in regulated markets, specifically targeting fertility treatment applications.
Shares of Glenmark were trading 0.34% down at ₹2,166.20 as of 11.49 am on the day of the announcement. As reported by CNBC TV18, the stock has delivered a 57% return over the past 12 months, demonstrating strong investor confidence in the company's growth strategy and regulatory successes. The stock performance reflects positive market sentiment toward Glenmark's continued regulatory achievements and expansion in the US generics market.
